CA3193939C - Crystalline forms of a pharmaceutical compound - Google Patents

Crystalline forms of a pharmaceutical compound Download PDF

Info

Publication number
CA3193939C
CA3193939C CA3193939A CA3193939A CA3193939C CA 3193939 C CA3193939 C CA 3193939C CA 3193939 A CA3193939 A CA 3193939A CA 3193939 A CA3193939 A CA 3193939A CA 3193939 C CA3193939 C CA 3193939C
Authority
CA
Canada
Prior art keywords
crystalline form
compound
disease
pharmaceutical composition
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3193939A
Other languages
English (en)
French (fr)
Other versions
CA3193939A1 (en
Inventor
Robert Hett
Fritz Blatter
Jennifer ROBIN
Kyle LANDSKRONER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azafaros BV
Original Assignee
Azafaros BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azafaros BV filed Critical Azafaros BV
Publication of CA3193939A1 publication Critical patent/CA3193939A1/en
Application granted granted Critical
Publication of CA3193939C publication Critical patent/CA3193939C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3193939A 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound Active CA3193939C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20199934.9A EP3978474A1 (en) 2020-10-02 2020-10-02 Crystalline forms of a pharmaceutical compound
EP20199934.9 2020-10-02
PCT/EP2021/077100 WO2022069709A1 (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound

Publications (2)

Publication Number Publication Date
CA3193939A1 CA3193939A1 (en) 2022-04-07
CA3193939C true CA3193939C (en) 2024-02-20

Family

ID=72744696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3193939A Active CA3193939C (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound

Country Status (19)

Country Link
US (2) US12116344B2 (cg-RX-API-DMAC10.html)
EP (3) EP3978474A1 (cg-RX-API-DMAC10.html)
JP (2) JP7809655B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240056628A (cg-RX-API-DMAC10.html)
CN (1) CN116390910A (cg-RX-API-DMAC10.html)
AU (2) AU2021353055B2 (cg-RX-API-DMAC10.html)
BR (2) BR122022018214A2 (cg-RX-API-DMAC10.html)
CA (1) CA3193939C (cg-RX-API-DMAC10.html)
CL (1) CL2023000943A1 (cg-RX-API-DMAC10.html)
DK (1) DK4114826T3 (cg-RX-API-DMAC10.html)
ES (1) ES2964105T3 (cg-RX-API-DMAC10.html)
FI (1) FI4114826T3 (cg-RX-API-DMAC10.html)
IL (2) IL316634A (cg-RX-API-DMAC10.html)
MA (1) MA58885B1 (cg-RX-API-DMAC10.html)
MX (1) MX2023003618A (cg-RX-API-DMAC10.html)
PE (1) PE20240138A1 (cg-RX-API-DMAC10.html)
TW (1) TWI912383B (cg-RX-API-DMAC10.html)
WO (1) WO2022069709A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202310184B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
EP4209215A1 (en) * 2022-01-10 2023-07-12 Azafaros B.V. Treatment of gm2 gangliosidosis
AU2025214578A1 (en) 2024-02-01 2026-08-13 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4595964A1 (en) 2024-02-01 2025-08-06 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4678174A1 (en) * 2024-07-11 2026-01-14 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders
WO2026013261A1 (en) * 2024-07-11 2026-01-15 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US20190195897A1 (en) * 2015-06-24 2019-06-27 Universiteit Leiden Glycosylated metabolites
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound

Also Published As

Publication number Publication date
WO2022069709A1 (en) 2022-04-07
JP7809655B2 (ja) 2026-02-02
AU2021353055B2 (en) 2022-10-06
TWI912383B (zh) 2026-01-21
TW202229236A (zh) 2022-08-01
EP3978474A1 (en) 2022-04-06
MX2023003618A (es) 2023-07-14
AU2022291486A1 (en) 2023-02-02
ES2964105T3 (es) 2024-04-04
FI4114826T3 (fi) 2023-11-21
IL301882B1 (en) 2024-12-01
EP4114826A1 (en) 2023-01-11
CL2023000943A1 (es) 2023-09-29
DK4114826T3 (da) 2023-11-13
PE20240138A1 (es) 2024-01-30
NZ798892A (en) 2023-09-29
IL301882A (en) 2023-06-01
CN116390910A (zh) 2023-07-04
KR20240056628A (ko) 2024-04-30
BR112022018020A2 (pt) 2023-04-18
JP2024054192A (ja) 2024-04-16
IL301882B2 (en) 2025-04-01
BR112022018020B1 (pt) 2023-12-26
EP4295847A3 (en) 2024-02-28
US20230391724A1 (en) 2023-12-07
ZA202310184B (en) 2024-01-31
AU2021353055A1 (en) 2022-09-15
KR20230078798A (ko) 2023-06-02
US12116344B2 (en) 2024-10-15
AU2022291486B2 (en) 2024-07-25
US20250059137A1 (en) 2025-02-20
KR102659466B1 (ko) 2024-04-19
US20240287001A9 (en) 2024-08-29
JP2023524169A (ja) 2023-06-08
CA3193939A1 (en) 2022-04-07
IL316634A (en) 2024-12-01
EP4295847A2 (en) 2023-12-27
MA58885B1 (fr) 2023-11-30
EP4114826B1 (en) 2023-08-23
BR122022018214A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
US12116344B2 (en) Crystalline forms of a pharmaceutical compound
EA019819B1 (ru) Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
US20250120958A1 (en) Treatment of GM2 Gangliosidosis
US20260062418A1 (en) Solid forms of posiphen d-tartrate
EP3505515B1 (en) Crystals of cyclic amine derivative and pharmaceutical use thereof
NZ798892B2 (en) Crystalline forms of a pharmaceutical compound
HK40087007B (en) Crystalline forms of a pharmaceutical compound
HK40087007A (en) Crystalline forms of a pharmaceutical compound
EA045552B1 (ru) Кристаллические формы фармацевтического соединения
EA052826B1 (ru) Кристаллические формы фармацевтического соединения
CN118632693A (zh) Gm2神经节苷脂贮积症的治疗

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230428

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250923